<DOC>
	<DOC>NCT00105144</DOC>
	<brief_summary>The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.</brief_summary>
	<brief_title>Study of Micafungin in Patients With Invasive Candidiasis or Candidemia</brief_title>
	<detailed_description>The purpose of the study is to determine the efficacy and safety of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia. The maximum length of antifungal treatment is 4 weeks except in pre-defined patients where maximum length of therapy is 8 weeks. A post treatment assessment will be conducted at 2 weeks and 6 weeks after the last dose of all antifungal treatments.</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Patients must have candidemia or invasive candidiasis. Patients who have received an echinocandin within one month prior to study entry. Patients who have received more than two days of prior systemic antifungal therapy for the current infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Investigational, Therapies</keyword>
	<keyword>Antifungal, Systemic</keyword>
	<keyword>Antibiotics, Antifungal</keyword>
	<keyword>Micafungin</keyword>
</DOC>